Comments
Commented by Armin Schulz on July 2nd, 2025 | 07:10 CEST
AI, personalized therapies, blockbusters: Evotec, NetraMark Holdings, Novo Nordisk – Your ticket to the pharmaceutical boom
As billion-dollar profits beckon and technological quantum leaps revolutionize the healthcare industry, investor excitement is surging in 2025. Investors are flocking back, attracted by unprecedented momentum. Artificial intelligence is discovering new drug candidates in record time, personalized medicine is unlocking entirely new markets, and solutions for widespread chronic diseases are driving valuations to dizzying heights. Those who understand the rules of this rapid change and identify the right partners are positioning themselves for exceptional returns. We therefore take a closer look at three compelling companies in this space: Evotec, NetraMark Holdings, and Novo Nordisk.
Read
Commented by Nico Popp on July 2nd, 2025 | 07:05 CEST
Is there a credit crunch coming? Alarm signals in the SME sector: Deutsche Bank, Commerzbank, Globex Mining
German SMEs are under pressure, struggling with the weight of the economic crisis, regulations and requirements, as well as increasingly poor financing conditions. According to Creditreform, German SMEs currently have little confidence in Germany as a business location. This mistrust is supported by a growing number of payment defaults. 11.2% of companies surveyed by Creditreform recently reported bad debt losses exceeding 1% of their turnover. Resourceful investors are already taking precautions.
Read
Commented by Armin Schulz on July 2nd, 2025 | 07:00 CEST
From microcap to market leader: How to get in on the booming billion-dollar graphene market with Argo Living Soils
Graphene sounds like something out of a science fiction novel, but it is already being used today where it matters most: in our roads and buildings. This miracle material, which is 200 times stronger than steel and as conductive as copper, is revolutionizing concrete and asphalt. It makes infrastructure more durable, drastically reduces CO₂ emissions, and lowers construction costs. For investors, this creates a perfect storm of technological advancement and sustainability pressure. Those who get in early with the companies driving this change will position themselves at the forefront of a billion-dollar market.
Read
Commented by Mario Hose on July 1st, 2025 | 09:25 CEST
Why Almonty Industries could become the BioNTech of critical metals
Between 2019 and 2021, investors in BioNTech witnessed a prime example of how a strategically relevant product – in this case, the COVID-19 vaccine – became a real stock market rocket thanks to government pressure, political support, and high public expectations. During this period, the share price rose from less than EUR 12.00 to over EUR 397.00. Those who invested early and were patient were able to achieve returns of over 3,200%. The decisive driver was not only technological innovation but also the government's determination to have the population vaccinated multiple times, which secured massive revenues for BioNTech. Today, a strikingly similar scenario is emerging with Almonty Industries (WKN: A1JSSD | ISIN: CA0203981034 | Ticker symbol: ALI) – only this time it is not about vaccines, but about the strategic raw material tungsten, which is indispensable for defense, aerospace, electronics, and mechanical engineering.
Read
Commented by André Will-Laudien on July 1st, 2025 | 07:20 CEST
Climate protection meets infrastructure: Argo Living relies on graphene for low-emission concrete
The construction industry is responsible for approximately 8% of global CO₂ emissions, and construction is taking place virtually everywhere. Anyone in the cement manufacturing industry who can significantly reduce greenhouse gas emissions is making a measurable impact on global climate targets. This creates visibility, political support, and ESG relevance, all of which are drivers for rising company valuations. The topic is highly relevant because several trillion USD will be invested in new infrastructure worldwide by 2050, including through programs such as the US Inflation Reduction Act (IRA), the EU Green Deal, and the reconstruction of Ukraine once the time comes. Investors are specifically looking for companies that are also included in these public budgets, as green building materials are considered a key technology. Argo Graphene Solutions (formerly Argo Living Soils) is perfecting this concept, and its stock is on the rise.
Read
Commented by Stefan Feulner on July 1st, 2025 | 07:10 CEST
Rheinmetall, Antimony Resources, Xiaomi – Right on trend
Although the air is getting thinner due to high valuations, especially on the US stock markets, the major indices are still striving for new highs, with the NASDAQ-100 technology exchange even climbing to another all-time high of over 22,660 points. In addition to popular defense stocks, companies involved in the production of critical metals are also trending strongly. In addition to tungsten producer Almonty Industries, another yet unknown player could soon be making a breakthrough.
Read
Commented by André Will-Laudien on July 1st, 2025 | 07:05 CEST
Innovation meets prevention: The next generation of security technologies from Volatus Aerospace
The world is in turmoil! Geopolitical conflicts, tensions between power blocs, and growing security requirements are straining public budgets and presenting governments and authorities worldwide with complex challenges. With the increasing use of digital solutions, human error must be minimized and excessive working hours reduced. This requires sophisticated technology to protect highly sensitive infrastructure such as energy, transportation, defense, and communications. As a rule, this infrastructure must be efficiently monitored and maintained for maintenance and liability reasons. In the digital age, every security-related decision is based on a foundation of data: high-resolution, up-to-date, and reliable. The regular collection and intelligent analysis of this data is essential for public institutions as well as for military applications. Volatus Aerospace (TSX-V: FLT; WKN: A2JEQU; ISIN: CA92865M1023) has its finger on the pulse!
Read
Commented by Nico Popp on July 1st, 2025 | 07:00 CEST
Disruption! Everything is changing: BioNxt Solutions, BioNTech, Bio-Rad Laboratories
The outbreak of the COVID-19 pandemic changed many things. True to the motto "just do it," companies like BioNTech have put their faith in mRNA technology—and within months, success followed, along with billions in revenue. Today, there are once again innovations with the potential to turn small companies into major cash cows. We explain what innovative healthcare companies BioNxt Solutions, BioNTech, and Bio-Rad Laboratories are currently working on and what potential this offers investors.
Read
Commented by Nico Popp on June 30th, 2025 | 07:40 CEST
Everything is going electric – and this detail could make investors wealthy: Power Metallic Mines, Rio Tinto, Freeport-McMoRan
The future is electric – heating systems and vehicles are already running on electricity today. Those with their own rooftop solar panels welcome this shift, as solar energy becomes essentially free after the initial investment. But this transition also requires massive investment. Experts at EY report that global electrification will require 115% more copper to be mined over the next thirty years than has been mined in all of human history. The scale of the challenge is, therefore, enormous. Making copper mining sustainable is even more so. But there are solutions.
Read
Commented by André Will-Laudien on June 30th, 2025 | 07:35 CEST
Takeover fever! Biotech and artificial intelligence boost Evotec, NetraMark Holdings, Novo Nordisk, and Bayer
The biotech sector is currently undergoing an exciting transformation, as big data and artificial intelligence are rapidly changing the way new drugs are discovered, developed, and tested. The use of learning algorithms allows molecular target structures to be identified more quickly and potential active ingredients to be evaluated more efficiently. Start-ups and established players alike are increasingly turning to data-driven platforms to reduce research costs and increase the success rate of clinical trials. As a result, capital is increasingly flowing into companies that use modern data analysis to drive biotechnology. Approaches that enable personalized medicine - treatments precisely tailored to an individual's specific condition - are in particularly high demand. For investors, this represents a promising growth sector with enormous disruptive potential. But who are the most interesting players?
Read